The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease

Movement Disorders

Volumn 23, Issue SUPPL. 3, 2008, Pages

  Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dyskinesias; Levodopa; Neuroprotection; Parkinson's disease; Toxicity

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FREE RADICAL; GLUTATHIONE; LEVODOPA; PLACEBO; PRAMIPEXOLE; ROPINIROLE;

ARTICLE; BLOOD BRAIN BARRIER; CELL LOSS; CELL PROTECTION; CELL SURVIVAL; CLINICAL TRIAL; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSKINESIA; EXCITOTOXICITY; HUMAN; LIFE EXPECTANCY; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; MOTOR DYSFUNCTION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; SYMPTOM;

ANIMALS; ANTIPARKINSON AGENTS; BLOOD-BRAIN BARRIER; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 53149110450     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22146     Document Type: Article

References (66)

1. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behaviour in diseases of the extrapyramidal system. Klin Wochenschr 1960;38:1236-1239.
2. Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Min Wochenschr 1961;73:787-788.
3. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
4. Hoehn MM. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992;10:331-339.
5. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
6. Kostic V, Przedborski S, Flaster E, Stemic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41:202-205.
7. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004; 19:997-1005.
8. Jenner PG, Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978;14:633-643.
9. Tse DC, McCreery RL, Adams RN. Potential oxidative pathways of brain catecholamines. J Med Chem 1976;19:37-40.
10. Adams RN, Murrill E, McCreery R, et al. 6-Hydroxydopamine, a new oxidation mechanism. Eur J Pharmacol 1972;17:287-292.
11. Youdim MB, Ben Shachar D, Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl 1989; 126:47-54.
12. Jenner PG, Fahn S. Levodopa-induced neurotoxicity. Does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 1997;8:376-393.
13. Shulman LM. Levodopa toxicity in Parkinson disease: reality or myth? Reality-practice patterns should change. Arch Neurol 2000;57:406-407.
14. Weiner WJ. Is levodopa toxic? Arch Neurol 2000;57:408-410.
15. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminium in Parkinson's disease: a LAMMA study. Brain Res 1992;593:343-346.
16. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982;33:305-310
17. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992;142:128-130.
18. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355.
19. Ambani LM, Van Woert MH, Murphy S. Brain peroxidase and catalase in Parkinson disease. Arch Neurol 1975;32:114-118.
20. Kish SJ, Morito C, Homykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 1985;58:343-346.
21. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 1991;101:198-203.
22. Cheng N, Maeda T, Kume T, et al. Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons. Brain Res 1996;743:278-283.
23. Mena MA, Casarejos MJ, Carazo A, et al. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-dopa toxicity. Neuroreport 1996;7:441-445.
24. Masserano JM, Gong L, Kulaga H, et al. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol Pharmacol 1996;50:1309-1315.
25. Hoyt KR, Reynolds IJ, Hastings TG. Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamateinduced cell death. Exp Neurol 1997; 143:269-281.
26. Ziv I, Zilkha-Falb R, Offen D, et al. Levodopa induces apoptosis in cultured neuronal cells-a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov Disord 1997;12:17-23.
27. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of Levodopa on mesencephalic cell cultures. J Neurochem 1993;61:1470-1478.
28. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-dopa in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 1997;69:1398-1408.
29. Clement MV, Long LH, Ramalingam J, Halliwell B. The cyto-toxicity of dopamine may be an artefact of cell culture. J Neurochem 2002;81:414-421.
30. Olanow CW, Gauger LL, Cedarbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann Neurol 1991;29:556-559.
31. Mena MA, Casarejos MJ, Carazo A, Paino CL, Garcia de Yebenes J. Glia protect fetal midbrain dopamine neurons in culture from L-dopa toxicity through multiple mechanisms. J Neural Transm 1997;104:317-328.
32. Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharm Exp Ther 2003;304:792-800.
33. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;1:1269.
34. Ben Shachar D, Zuk R, Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 1995;64:718-723.
35. Dagani F, Ferrari R, Anderson JJ, Chase TN. Levodopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria. Mov Disord 1991;6:315-319.
36. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD. Anatomic and disease specificity of NADH CoQ1 reductase (complex 1) deficiency in Parkinson's disease. J Neurochem 1990;55:214214-214215.
37. Sanchez-Ramos J, Overvik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994;3:197-204.
38. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsoman brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997;69: 1196-1203.
39. Zhang J, Perry G, Smith MA, et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 1999;154:1423-1429.
40. Hartley A, Stone JM, Heron C, Cooper JM, Schapira AHV. Complex I inhibitors induce dose dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 1994;63: 1987-1990.
41. Ziv I, Melamed E, Nardi N, et al. Dopamine induces apoptosis-like cell death in cultured sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett 1994;170:136-140.
42. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-dopa. Implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-2464.
43. Ogawa N, Edamatsu R, Mizukawa K, et al. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. Adv Neurol 1993;60:242-250.
44. Ogawa N, Asanuma M, Kondo Y, et al. Differential effects of chronic Levodopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci Lett 1994;171:55-58.
45. Ogawa N. Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages. Eur Neurol 1994;34:20-28.
46. Maharaj H, Sukhdev MD, Scheepers M, Mokokong R, Daya S. Levodopa administration enhances 6-hydroxydopamine generation. Brain Res 2005;1063:180-186.
47. Hefti F, Melamed E, Bhawan J, Wurtman R. Long term administration of Levodopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195.
48. Ferrario JE, Taravini IR, Mourlevat S, et al. Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. J Neurochem 2004;90:1348-58.
49. Perry TL, Yong VW, Ito M, et al. Nigrostriatal Dopaminergic neurons remain undamaged in rats given high doses of Levodopa and carbidopa chronically. J Neurochem 1984;43:990-993.
50. Lyras L, Zeng BY, McKenzie G, et al. Chronic high dose Levodopa alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J Neural Transm 2002;109:53-67.
51. Schapira AH. Etiology of Parkinson's disease. Neurology 2006; 66:S10-S23.
52. Casarejos MJ, Solano RM, Menendez J, et al. Differential effects of Levodopa on monoamine metabolism, cell survival and glutathione production in midbrain neuronal-enriched cultures from parkin knockout and wild-type mice. J Neurochem 2005;94: 1005-1014.
53. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
54. Rajput AH, Fenton M, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997;12:634-638.
55. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
56. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
57. Schapira AH, Olanow CW. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol 2003;53:S149-S157.
58. Schapira AH. Neuroprotection and dopamine agonists. Neurology 2002;58:S9-S18.
59. Gu M, Iravani MM, Cooper JM, King D, Jenner P, Schapira. AH. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. I Neurochem 2004;91:1075-1081.
60. Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 2001;18:389-396.
61. Nair VD, Olanow CW, Sealfon SC. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 2003;373:25-32.
62. Iravani MM, Haddon CO, Cooper JM, Jenner P, Schapira AH. Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 2006;96:1315-1321.
63. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions JAMA 2004;291: 358-364.
64. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003;60:381-389.
65. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59:559-562.
66. Schapira AH. Treatment options in the models management of Parkinson's disease. Arch Neurol 2007;64:1083-1088.